This clinical trial is focused on studying the effects of a treatment on patients with Diabetes Mellitus, which includes both type 1 and type 2 diabetes, and conditions related to bone health such as osteopenia and osteoporosis. The treatment being tested is a medication called Alendronate, which is commonly used to strengthen bones. The study will also involve a comparison with a placebo, which is a substance with no active medication.
The purpose of the study is to investigate how Alendronate affects markers related to bone health and blood sugar control in patients with diabetes. Participants will take the medication in the form of tablets, and the study will monitor changes in their bone and blood sugar markers over time. The study will last for a period of up to 24 months, during which participants will have regular check-ups to assess their health and the effects of the treatment.
Throughout the study, various health indicators will be measured, including HbA1c (a marker of blood sugar levels), bone density, and other substances in the blood that can provide information about bone and metabolic health. The study aims to provide insights into how Alendronate can benefit patients with diabetes who also have concerns about their bone health.



Denmark